Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Advanced Cancer 4Melanoma 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Nivolumab 11Ipilimumab 6linrodostat 4relatlimab 3Pemetrexed 2tislelizumab 1regorafenib 1ralimetinib 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1gedatolisib 1figitumumab 1efatutazone 1abemaciclib 1Vorinostat 1Tetanus Toxoid 1Tamoxifen 1Sunitinib 1Ranitidine 1Midazolam 1LY2603618 1LY2584702 1Irinotecan 1Gemcitabine 1Fulvestrant 1Dasatinib 1Cyclophosphamide 1Crizotinib 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Advanced Cancer × linrodostat × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

NCT02996110 2022-12-19

FRACTION-RCC

Bristol-Myers Squibb

Phase 2 Completed
182 enrolled 23 charts

Advanced Cancer

NCT03792750 2022-02-28

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
12 enrolled 26 charts

Advanced Cancer

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated
295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡